Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 1
1956 1
1959 1
1961 1
1962 4
1964 2
1965 3
1966 4
1967 5
1968 4
1969 7
1970 4
1971 4
1972 7
1973 6
1974 4
1975 7
1976 5
1977 6
1978 2
1979 5
1980 8
1981 8
1982 9
1983 13
1984 13
1985 23
1986 11
1987 13
1988 6
1989 15
1990 7
1991 8
1992 4
1993 9
1994 13
1995 10
1996 22
1997 18
1998 16
1999 25
2000 19
2001 17
2002 21
2003 26
2004 32
2005 49
2006 65
2007 63
2008 73
2009 78
2010 96
2011 87
2012 115
2013 126
2014 156
2015 146
2016 190
2017 196
2018 209
2019 239
2020 312
2021 329
2022 341
2023 376
2024 114

Text availability

Article attribute

Article type

Publication date

Search Results

3,370 results

Results by year

Filters applied: . Clear all
Page 1
Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension.
Desai AS, Webb DJ, Taubel J, Casey S, Cheng Y, Robbie GJ, Foster D, Huang SA, Rhyee S, Sweetser MT, Bakris GL. Desai AS, et al. N Engl J Med. 2023 Jul 20;389(3):228-238. doi: 10.1056/NEJMoa2208391. N Engl J Med. 2023. PMID: 37467498 Clinical Trial.
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer.
Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, Lihm J, Ceglia N, Guasp P, Chu A, Yu R, Chandra AK, Waters T, Ruan J, Amisaki M, Zebboudj A, Odgerel Z, Payne G, Derhovanessian E, Müller F, Rhee I, Yadav M, Dobrin A, Sadelain M, Łuksza M, Cohen N, Tang L, Basturk O, Gönen M, Katz S, Do RK, Epstein AS, Momtaz P, Park W, Sugarman R, Varghese AM, Won E, Desai A, Wei AC, D'Angelica MI, Kingham TP, Mellman I, Merghoub T, Wolchok JD, Sahin U, Türeci Ö, Greenbaum BD, Jarnagin WR, Drebin J, O'Reilly EM, Balachandran VP. Rojas LA, et al. Among authors: desai a. Nature. 2023 Jun;618(7963):144-150. doi: 10.1038/s41586-023-06063-y. Epub 2023 May 10. Nature. 2023. PMID: 37165196 Free PMC article. Clinical Trial.
SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials.
Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, McMurray JJV, Solomon SD. Vaduganathan M, et al. Among authors: desai as. Lancet. 2022 Sep 3;400(10354):757-767. doi: 10.1016/S0140-6736(22)01429-5. Epub 2022 Aug 27. Lancet. 2022. PMID: 36041474
Lung Cancer Treatment Advances in 2022.
Abu Rous F, Singhi EK, Sridhar A, Faisal MS, Desai A. Abu Rous F, et al. Among authors: desai a. Cancer Invest. 2023 Jan;41(1):12-24. doi: 10.1080/07357907.2022.2119479. Epub 2022 Dec 12. Cancer Invest. 2023. PMID: 36036470
Immunotherapy-based combinations in metastatic NSCLC.
Desai A, Peters S. Desai A, et al. Cancer Treat Rev. 2023 May;116:102545. doi: 10.1016/j.ctrv.2023.102545. Epub 2023 Mar 27. Cancer Treat Rev. 2023. PMID: 37030062 Free article. Review.
Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER.
Jhund PS, Kondo T, Butt JH, Docherty KF, Claggett BL, Desai AS, Vaduganathan M, Gasparyan SB, Bengtsson O, Lindholm D, Petersson M, Langkilde AM, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Køber L, Lam CSP, Martinez FA, Sabatine MS, Shah SJ, Solomon SD, McMurray JJV. Jhund PS, et al. Among authors: desai as. Nat Med. 2022 Sep;28(9):1956-1964. doi: 10.1038/s41591-022-01971-4. Epub 2022 Aug 27. Nat Med. 2022. PMID: 36030328 Free PMC article.
Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Randomized Clinical Trial.
Mc Causland FR, Claggett BL, Vaduganathan M, Desai AS, Jhund P, de Boer RA, Docherty K, Fang J, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Saraiva JFK, McGrath MM, Shah SJ, Verma S, Langkilde AM, Petersson M, McMurray JJV, Solomon SD. Mc Causland FR, et al. Among authors: desai as. JAMA Cardiol. 2023 Jan 1;8(1):56-65. doi: 10.1001/jamacardio.2022.4210. JAMA Cardiol. 2023. PMID: 36326604 Free PMC article. Clinical Trial.
Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure.
Mentz RJ, Ward JH, Hernandez AF, Lepage S, Morrow DA, Sarwat S, Sharma K, Starling RC, Velazquez EJ, Williamson KM, Desai AS, Zieroth S, Solomon SD, Braunwald E; PARAGLIDE-HF Investigators. Mentz RJ, et al. Among authors: desai as. J Am Coll Cardiol. 2023 Jul 4;82(1):1-12. doi: 10.1016/j.jacc.2023.04.019. Epub 2023 May 21. J Am Coll Cardiol. 2023. PMID: 37212758 Free article. Clinical Trial.
Drugging KRAS: current perspectives and state-of-art review.
Parikh K, Banna G, Liu SV, Friedlaender A, Desai A, Subbiah V, Addeo A. Parikh K, et al. Among authors: desai a. J Hematol Oncol. 2022 Oct 25;15(1):152. doi: 10.1186/s13045-022-01375-4. J Hematol Oncol. 2022. PMID: 36284306 Free PMC article. Review.
3,370 results